Complete Response from FDA for Keytruda + Lenvima combination to treat hepatocellular carcinoma ( Liver Cancer)- Merck Inc. + Eisai
Eisai Co., Ltd. and Merck & Co., Inc., announced that the FDA has issued a Complete Response Letter (CRL) regarding Eisai’s and Merck’s applications seeking accelerated approval of… read more.